Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The HCV Race: Gilead Plowing Ahead With ‘7977; Bristol Eyes First-To-Market Opportunity With All-Oral Combo In Asia

This article was originally published in PharmAsia News

Executive Summary

Several companies developing candidates for hepatitis C updated their plans during the recent round of quarterly earnings calls, outlining everything from strategies to be first-to-market with an all-oral combination of direct-acting antivirals to an emerging market strategy for pegylated interferon.


Related Content

High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts